LNTH Q2 2024 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$394M+22.5% YoY

Gross Profit

$256M64.9% margin

Operating Income

$103M26.1% margin

Net Income

$62M15.8% margin

EPS (Diluted)

$0.88

QoQ Revenue Growth

+6.5%

Cash Flow

Operating Cash Flow

$85M

Free Cash Flow

$74M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$913M

Stockholders' Equity

$1.0B

Cash & Equivalents

$757M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$394M	$322M	+22.5%
Gross Profit	$256M	$203M	+26.2%
Operating Income	$103M	$124M	-17.2%
Net Income	$62M	$94M	-34.1%

Revenue Segments

Product

$393M33%

Radiopharmaceutical Oncology

$273M23%

PYLARIFY

$273M23%

Total Precision Diagnostics

$112M10%

DEFINITY

$78M7%

Techne Lite

$28M2%

Strategic Partnerships And Other

$9M1%

Other Precision Diagnostics

$6M0%

License and Royalty Revenues

$1M0%